Latest Health News

Ashley Services Group delivered a standout FY26 with revenue up 16.7% to $602.2 million and net profit after tax surging 189.5% to $6.29 million, supported by margin gains across key sectors and a strategic acquisition.

ECS Botanics boosted revenue by 10% to $21.4 million in FY26, delivering positive EBITDA and operating cash flow while advancing international market entry and branded product growth.

Austral Gold nearly doubled its gold equivalent production in the first half of 2026, driven by the Casposo restart and Guanaco operations, delivering a US$15.5 million net profit and extending Guanaco’s mine life to 14 years.

Percheron Therapeutics has partnered with Vanderbilt Health to initiate a clinical trial testing HMBD-002 in combination with standard treatments for high-risk acute myeloid leukaemia and myelodysplastic syndrome, targeting a recruitment start in late 2026.

LTR Pharma is shifting gears from clinical trials to commercial rollout, securing US partnerships for ROXUS and reporting encouraging SPONTAN Phase II data that supports FDA approval ambitions.

Comvita Limited has swung back to profitability in FY26, reporting $7.7 million net profit after a $40.5 million capital raise that brought Southeast Asian consumer giant F&N Ventures on board with a near 20% stake.

Bentley Capital Limited swung back to profitability in FY2026, posting a $255,000 net profit driven mainly by legal settlements and modest investment gains, reversing a prior loss of $878,000.

Austco Healthcare has delivered record FY26 financial results, driven by strong organic growth, acquisitions, and a growing software maintenance base, positioning the company for sustained earnings momentum.

Rhythm Biosciences marked its transition to commercialisation with first sales of ColoSTAT® and geneType™ tests, despite a 55% increase in loss to $5.93 million. The company expanded market access and secured manufacturing agreements, while NHS England began evaluating ColoSTAT® for bowel cancer screening.

Nuchev Limited grew revenue by 12% in FY26, driven by domestic expansion, yet saw margins contract and adjusted EBITDA losses deepen to A$4.6 million. The company’s FY27 focus shifts to margin improvement, operating leverage, and cash conversion.

Careteq Limited (ASX: CTQ) reported a $398K net loss for FY26 amid a strategic reset that included selling its Embedded Health Solutions business and repaying all debt. The company now pivots fully to growing its HMR Referrals platform with $3.19 million cash on hand.

Global Health Limited trimmed its FY26 net loss by 12.5% to A$758,220, driven by a 5.5% lift in recurring SaaS revenue and a 20% cut in employee costs aided by AI integration, though going concern risks remain.